By Sharecast
Date: Tuesday 23 Dec 2025
By Josh White
Date: Wednesday 26 Mar 2025
(Sharecast News) - Diaceutics announced on Wednesday that it has strengthened its commercial partnership with Partner Therapeutics, the new US licence holder of the oncology precision medicine 'Bizengri', or zenocutuzumab, with an enhanced multi-year agreement for its PMx commercialisation services.
By Josh White
Date: Tuesday 17 Dec 2024
(Sharecast News) - Diaceutics announced on Tuesday that it has won a $5.1m contract with a global pharmaceutical company to deliver laboratory engagement services through its DXRX platform.
| Currency | UK Pounds |
| Share Price | 137.86p |
| Change Today | 6.86p |
| % Change | 5.23 % |
| 52 Week High | 168.00p |
| 52 Week Low | 108.00p |
| Volume | 116,900 |
| Shares Issued | 84.90m |
| Market Cap | £117.04m |
| Beta | 0.44 |
| RiskGrade | 196 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 12:36 | 10,000 @ 137.25p |
| 12:35 | 7,500 @ 137.50p |
| 12:35 | 7,500 @ 137.50p |
| 10:24 | 25,000 @ 137.00p |
| 11:19 | 1,500 @ 138.00p |
| CEO | Ryan Gerard Keeling |
| CFO | Nick Roberts |
You are here: research